Please login to the form below
Dermavant
This page shows the latest Dermavant news and features for those working in and with pharma, biotech and healthcare.
Urovant slips on phase 3 incontinence drug data
Others cued up for results include phase 3 trials of Myovant’s relugolix in uterine fibroids, endometriosis and prostate cancer, and Dermavant’s tapinarof in psoriasis.
Latest news
-
GSK sells eczema and psoriasis drug to Dermavant for £250m
Psoriasis and atopic dermatitis (eczema) candidate tapinarof is being transferred to Roivant Sciences group company Dermavant in return for £150m upfront and another £100m in the offing if it meets development
-
Roivant gets $1.1bn investment from Japan's SoftBank
Roivant - the holding company for subsidiaries Axovant, Myovant, Dermavant, Enzyvant and just-launched urology specialist Urovant - said the cash injection will be used to launch new subsidiaries "within and beyond the
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Dermavant strengthens executive team
Dermavant Sciences, a biopharmaceutical company focused on delivering therapies for dermatologic conditions, has bolstered its executive team with the addition of four new hires. ... Peterson, who previously worked at Sienna Biopharmaceuticals as its
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Lead Copywriter
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Account Director
-
Competitive
-
Medical Editor
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Pfizer introduces new logo in a ‘shift from commerce to science’
- New study identifies drugs that are safe to use in COVID-19 treatment
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
90TEN
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
